Core Viewpoint - The company announces the right for holders of "Huahai Convertible Bonds" to sell back part or all of their unconverted bonds, with a buyback price set at RMB 100.30 per bond, including accrued interest and tax [1][4]. Group 1: Buyback Terms - Holders of "Huahai Convertible Bonds" can exercise their right to sell back the bonds if the company's stock price remains below 70% of the conversion price for 30 consecutive trading days during the last two interest years of the bond [2]. - The buyback price is calculated to include accrued interest, which for the sixth year at a coupon rate of 2.00% over 54 days amounts to approximately RMB 0.30 per bond, leading to a total buyback price of RMB 100.30 [5][10]. - The buyback period is set from December 22, 2025, to December 26, 2025, with funds to be disbursed on December 31, 2025 [4][11]. Group 2: Buyback Process - The buyback is voluntary, allowing bondholders to choose whether to participate [6]. - Bondholders must submit their buyback requests through the Shanghai Stock Exchange trading system during the specified buyback period [7]. - If a buyback request is not successful on the first day, bondholders may continue to submit requests on subsequent days within the buyback period [8]. Group 3: Trading During Buyback - "Huahai Convertible Bonds" will continue to trade during the buyback period but will not be convertible into shares [13]. - If the total face value of the bonds in circulation falls below RMB 30 million due to the buyback, trading will still continue until the end of the buyback period [13].

证券代码：600521 证券简称：华海药业 公告编号：临 2025-127 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于"华海转债"可选择回售的第五次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

Core Viewpoint - The announcement details the fourth notice regarding the optional redemption of the "Huahai Convertible Bonds," allowing bondholders to sell their bonds back to the company at a specified price under certain conditions [1][2]. Group 1: Redemption Terms - The redemption price is set at 100.30 RMB per bond, which includes accrued interest and tax [2][10]. - Bondholders have the option to redeem part or all of their unconverted convertible bonds, and this redemption is not mandatory [2][6]. - The redemption clause becomes effective if the company's stock price remains below 70% of the conversion price for 30 consecutive trading days [2][3]. Group 2: Redemption Process - The redemption period is from December 22, 2025, to December 26, 2025, during which the bonds will stop being convertible [4][9]. - The payment date for the redeemed bonds is set for December 31, 2025 [11]. - Bondholders must submit their redemption requests through the Shanghai Stock Exchange trading system during the specified redemption period [7][8]. Group 3: Interest Calculation - The accrued interest for the redemption is calculated using the formula: IA = B × i × t / 365, where B is the total face value of the bonds being redeemed, i is the annual coupon rate, and t is the number of days from the last interest payment to the redemption date [5]. - For the sixth year, the coupon rate is 2.00%, and the interest calculated for 54 days is approximately 0.30 RMB per bond, confirming the total redemption price of 100.30 RMB [5][10]. Group 4: Trading During Redemption Period - The "Huahai Convertible Bonds" will continue to trade during the redemption period but will not be convertible [13]. - If the total face value of the bonds in circulation falls below 30 million RMB due to redemptions, trading will continue until the end of the redemption period, after which an announcement will be made [13].

证券代码：600521 证券简称：华海药业 公告编号：临 2025-126 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于"华海转债"可选择回售的第四次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

Core Viewpoint - The company announces the right for holders of "Huahai Convertible Bonds" to sell back part or all of their unconverted bonds under specific conditions, with a buyback price set at RMB 100.30 per bond, including accrued interest and tax [1][4][10]. Group 1: Buyback Terms - Holders of "Huahai Convertible Bonds" can exercise their right to sell back the bonds if the company's stock price remains below 70% of the conversion price for 30 consecutive trading days during the last two interest years of the bond [2][6]. - The buyback price is calculated to include accrued interest, which for the sixth year at a coupon rate of 2.00% over 54 days amounts to approximately RMB 0.30 per bond, leading to a total buyback price of RMB 100.30 [5][10]. Group 2: Buyback Period and Procedures - The buyback period is set from December 22, 2025, to December 26, 2025, with funds to be disbursed on December 31, 2025 [4][11]. - During the buyback period, "Huahai Convertible Bonds" will continue to trade but will not be convertible into shares [13]. Group 3: Additional Information - If the total face value of the bonds in circulation falls below RMB 30 million due to the buyback, trading will continue until the end of the buyback period, after which an announcement will be made [13]. - The company will disclose the results of the buyback and its impact on the company after the buyback period concludes [12].

关于"华海转债"可选择回售的第三次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600521 证券简称：华海药业 公告编号：临 2025-125 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

Group 1: Monetary Policy and Economic Outlook - The monetary policy in 2026 will continue to align with fiscal measures, supporting debt sustainability and fiscal health [2][12] - Interest rate cuts in 2026 may remain restrained due to reduced urgency from anti-involution trends, with a higher probability of one rate cut rather than two [2][12] - The international economic struggle will have financial implications, particularly for the internationalization of the RMB amid intensified US-China competition [2][12] Group 2: Misunderstandings about "Deposit Migration" - There are three main misunderstandings regarding "deposit migration": underestimating excess savings, the speed of market entry, and the investment attributes of excess savings [3][14] - The potential scale of excess savings is estimated to exceed 9.4 trillion, indicating significant funds could enter the stock market [3][14] - The speed of funds entering the market may be underestimated due to reliance on non-bank deposit tracking, which does not accurately reflect the migration of resident funds [3][14] Group 3: Huahai Pharmaceutical (600521) Analysis - Huahai Pharmaceutical is a leading domestic producer of specialty APIs, with a strong focus on global formulation strategies [4][13] - The company has applied for over 70 domestic and international patents in the field of biopharmaceuticals, particularly in immunology and oncology [4][17] - The projected revenue for Huahai Pharmaceutical from 2025 to 2027 is expected to be 8.632 billion, 9.413 billion, and 10.282 billion respectively, with a target market value indicating a potential upside of 30.04% [4][17]

证券代码：600521 证券简称：华海药业 公告编号：临 2025-124 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于"华海转债"可选择回售的第二次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）的股票自 2025 年 11 月 2 日 至 2025 年 12 月 12 日连续 30 个交易日收盘价格低于公司可转换公司债券（以下 简称"华海转债"）当期转股价格的 70%。根据《浙江华海药业股份有限公司公开 发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）的约定，可转债 回售条款生效。 现依据《上市公司证券发行管理办法》《可转换公司债券管理办法》《上海证 券交易所股票上市规则》和《募集说明书》等有关规定，就回售有关事项向全体 "华海转债"持有人公告如下： 一、回售条款 1 / 3 回售价格：100.30 元人民币/张（含当期利息、含税） 回售期：2025 年 12 月 22 日至 2025 年 12 月 26 ...

浙江华海药业股份有限公司 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2025-123 号 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 关于公司及下属子公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 案件所处的诉讼阶段：Gaston Roberts（以下简称"原告"或"上诉人"） 人身损害赔偿案件（以下简称"Gaston Roberts 案件"），原告就一审驳回原告起 诉的简易判决提起上诉。 上市公司及其子公司所处的当事人地位：被上诉人。 涉诉金额：上诉人未明确具体金额。 月 31 日刊登在中国证券报、上海证券报、证券时报、证券日报及上海证券交易 所网站（www.sse.com.cn）上的《浙江华海药业股份有限公司关于公司及其下属 子公司涉及诉讼的公告》（公告编号：临 2018-088 号）、《浙江华海药业股份有限 公司关于公司及其下属子公司涉及诉讼的补充公告》（公告编号：临 ...

Core Viewpoint - Huahai Pharmaceutical announced that the plaintiff in the Gaston Roberts personal injury compensation case has appealed the judgment that dismissed the lawsuit, with the company as the appellee. The amount involved in the appeal has not been specified. The appeal process has just begun and is in its early stages, making it difficult for the company to assess the impact on its financial results, which will depend on subsequent court rulings or enforcement outcomes. Aside from this case, there are no significant developments in other valsartan lawsuits in the U.S., and the outcomes remain uncertain [1]. Group 1 - The plaintiff in the Gaston Roberts case has appealed the dismissal of the lawsuit [1] - The company is currently unable to determine the financial impact of the appeal [1] - There are no significant updates on other valsartan lawsuits in the U.S. [1]